Patent · US Active

Compositions and methods for inhibition of expression of protein C (PROC) genes

US11118181B2 · kind B2 · utility

0Cited by

5References

20Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Ivanka Toudjarska · Medford, US
John M. Maraganore · Concord, US
Brian Bettencourt · Groton, US
Stuart Milstein · Cambridge, US
Martin Maier · Cambridge, US
Klaus Charisse · Acton, US
Kallanthottathil G. Rajeev · Wayland, US
Satyanarayana Kuchimanchi · Cambridge, US

Key dates

Filing date	Nov 11, 2019
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Nov 11, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3521
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.